Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
60.60
-0.08 (-0.13%)
At close: Mar 28, 2025, 4:00 PM
60.64
+0.04 (0.06%)
After-hours: Mar 28, 2025, 7:57 PM EDT
Incyte Revenue
In the year 2024, Incyte had annual revenue of $4.24B with 14.76% growth. Incyte had revenue of $1.18B in the quarter ending December 31, 2024, with 16.32% growth.
Revenue (ttm)
$4.24B
Revenue Growth
+14.76%
P/S Ratio
2.96
Revenue / Employee
$1,620,641
Employees
2,617
Market Cap
11.73B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionINCY News
- 2 days ago - Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico - GlobeNewsWire
- 10 days ago - Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib - Seeking Alpha
- 11 days ago - Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results - Investopedia
- 11 days ago - Incyte Is Today's Worst S&P 500 Stock. Here's Why. - Barrons
- 11 days ago - Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls - Benzinga
- 11 days ago - Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 12 days ago - Incyte's skin disease drug meets main goal in two late-stage studies - Reuters
- 12 days ago - Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa - Business Wire